CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications-Reference-Cited by-同舟云学术

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

Published:2013-04-16 Issue:1 Volume:28 Page:155-165
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Tai Y-T,Landesman Y,Acharya C,Calle Y,Zhong M Y,Cea M,Tannenbaum D,Cagnetta A,Reagan M,Munshi A A,Senapedis W,Saint-Martin J-R,Kashyap T,Shacham S,Kauffman M,Gu Y,Wu L,Ghobrial I,Zhan F,Kung A L,Schey S A,Richardson P,Munshi N C,Anderson K C

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2013115.pdf

Reference46 articles.

1. Xu D, Grishin NV, Chook YM . NESdb: a database of NES-containing CRM1 cargos. Mol Biol Cell 2012; 23: 3673–3676.

2. Kanai M, Hanashiro K, Kim SH, Hanai S, Boulares AH, Miwa M et al. Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat Cell Biol 2007; 9: 1175–1183.

3. Shao C, Lu C, Chen L, Koty PP, Cobos E, Gao W . p53-Dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother Pharmacol 2011; 67: 1369–1380.

4. Turner JG, Dawson J, Sullivan DM . Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012; 83: 1021–1032.

5. Vogt PK, Jiang H, Aoki M . Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle 2005; 4: 908–913.

Cited by 251 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma;Cancer Letters;2024-08

2. Antitumor activity and low gastrointestinal toxicity of a novel selective inhibitor of nuclear export, SZJK-0421, in multiple myeloma;Acta Pharmaceutica Sinica B;2024-07

3. Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review;Cancer Drug Resistance;2024-06-26

4. Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality?;International Journal of Molecular Sciences;2024-06-01

5. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study;Gynecologic Oncology;2024-06